Virtual high throughput screening in new lead identification

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 10, 2011, Pages 840-860

  Badrinarayan, Preethi ^a   Sastry, G Narahari ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Kinase; Lead design; Molecular representations; Virtual screening

Indexed keywords

CILOMILAST; DORAMAPIMOD; G PROTEIN COUPLED RECEPTOR; IMATINIB; LAPATINIB; LIGAND; PHOSPHODIESTERASE V INHIBITOR; ROFLUMILAST; ROLIPRAM; SORAFENIB; THEOPHYLLINE;

ALLOSTERISM; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DATA BASE; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; NAUSEA; PHARMACOPHORE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM CHEMISTRY; RELIABILITY; SOLVATION; VIRTUAL REALITY; VOMITING;

ANIMALS; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY;

EID: 80054930821     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620711797537102     Document Type: Article

References (207)

1. Reddy, A. S.; Pati, S. P.; Kumar, P. P.; Pradeep, H. N.; and Sastry, G. N. Virtual screening in drug discovery - A computational perspective. Curr. Prot. Peptide Sci., 2007, 8, 329-351. (Pubitemid 47317040)
2. Jorgensen, W. L. Efficient drug lead discovery and optimization. Acc. Chem. Res., 2009, 42, 724-733.
3. Koppen, H. Virtual screening: what does it give us? Curr. Opin. Drug Discov. Devel., 2009, 12, 397-407.
4. Schneider, G. Virtual screening: an endless staircase? Nat. Rev. Drug Discovery, 2010, 9, 273-276.
5. Bajorath, J. Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening. J. Chem. Inf. Comput. Sci., 2001, 41, 233-245. (Pubitemid 33717130)
6. Bender, A.; Jenkins, J. L.; Scheiber, J.; Sukuru, S. C. K.; Glick, M.; Davies, J. W. How Similar Are Similarity Searching Methods? A principal component analysis of molecular descriptor space. J. Chem. Inf. Model., 2009, 49, 108-119.
7. Sastry, M.; Lowrie, J. F.; Dixon, S. L.; Sherman, W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J. Chem. Inf. Model., 2010, 50, 771-784.
8. Nisius, B.; Bajorath, J. Fingerprint recombination - generating hybrid fingerprints for similarity searching from different fingerprint Types. Chem. Med. Chem., 2009, 4, 1859-1863.
9. Reddy, A. S.; Amarnath, H. S. D.; Bapi, R. S.; Sastry G. M.; Sastry, G. N. Protein ligand interaction database (PLID): Datamining analysis of structure-function relationships. Comp. Biol. Chem., 2008, 32, 387-390.
10. Wang, Y.; Xiao, J.; Suzek, T. O.; Zhang, J.; Wang, J.; Bryant, S. H. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res., 2009, 37, W623-33.
11. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res., 2000, 28, 27-30. (Pubitemid 30047706)
12. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey J. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 2006, 34, 668-672.
13. Irwin, J. J.; Shoichet, B. K. ZINC - A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005, 45, 177-182. (Pubitemid 40736970)
14. Blum, L. C.; Reymond J. L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. J. Am. Chem. Soc., 2009, 131, 8732-8733.
15. Karla, K.; Donna, K.; Coyne, B.; Williams, M. Target identification and validation in drug discovery: The role of proteomics. Biochem. Pharmacol., 2005, 69, 1133-1139. (Pubitemid 40417484)
16. Perot, S.; Sperandio, O.; Miteva, M. A.; Camproux, A. C.; Villoutreix, B. O. Druggable pockets and binding site centric chemical space: A paradigm shift in drug discovery. Drug Discov. Today, 2010, 15, 656-667.
17. Fuller, J. C.; Burgoyne, N. J.; Jackson, R. M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today, 2009, 14, 155-161.
18. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high throughput method for detection of drug binding sites J. Med. Chem., 2010, 53, 5858-5867.
19. Bakheet, T. M.; Doig, A. J. Properties and identification of human protein drug targets. Bioinformatics, 2009, 25, 451-457.
20. Sakharkar, K. R.; Sakharkar, M. K.; Vincent, Chow, T. K. Biocomputational strategies for microbial drug target identification. Methods in Molecular Medicine, 142, New Antibiotic Targets Edited by: W. Scott Champney, Humana Press Inc., Totowa, NJ. 1-9
21. Shena, Y.; Liub, J.; Estiua, G.; Isinb, B.; Ahnc, Y. Y.; Leec, D. S.; Barabásic, A. L.; Kapatrale, V.; Wiesta, O.; Oltvaib, Z. N. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 1082-1087.
22. Willett, P. Searching techniques for databases of two- and three dimensional chemical structures. J. Med. Chem., 2005, 48, 4183-4199. (Pubitemid 40884919)
23. Eckert, H.; Bajorath J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov. Today, 2007, 12, 225-233.
24. Brown, R. D.; Martin, Y. C. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. J. Chem. Inf. Comput. Sci. 1997, 37, 1-9. (Pubitemid 127601574)
25. Ewing, T.; Baber, J. C.; Feher, M. Novel 2D fingerprints for ligand-based virtual screening. J. Chem. Inf. Model., 2006, 46, 2423-2431. (Pubitemid 46008115)
26. Zavodszky, M. I.; Rohatgi, A.; Voorst, V. J. R.; Yan, H.; Kuhn, L. A. scoring ligand similarity in structure-based virtual screening. J. Mol. Recognit. 2009, 22, 280-292.
27. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. J. Chem. Inf. Comput. Sci., 2004, 44, 1177-1185.
28. Brown, R. D.; Martin, Y. C. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. J. Chem. Inf. Comput. Sci. 1997, 37, 1-9. (Pubitemid 127601574)
29. Willett, P.; Winterman, V. A comparison of some measures for the determination of intermolecular structural similarity measures of intermolecular structural similarity. Quan. Struct. Activ. Relat., 1986, 5, 18-25. (Pubitemid 16134330)
30. Breda, A.; Basso, L. A.; Santos, D. S.; de Azevedo, Jr. W.F. Virtual screening of drugs: Score functions, docking, and drug design. Current Comput.-Aid. Drug Des., 2008, 4, 265-272.
31. Seifert, M. H. Targeted scoring functions for virtual screening. Drug Discov. Today, 2009, 14, 562-569.
32. Grant, J.A.; Pickup, B. T.; Nicholls, A. A smooth permitivity function for Poisson-Boltzman solvation methods. J. Comp. Chem., 2001, 22, 608-640. (Pubitemid 32382607)
33. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol., 2000, 295, 337-356. (Pubitemid 30045364)
34. Muegge, I. A knowledge-based scoring function for protein-ligand interactions: probing the reference state. Perspect. Drug Des. Discov., 2000, 20, 99-114.
35. Scharer, K.; Morgenthaler, M.; Paulini, R.; Obst, S. U.; Banner, D. W.; Schlatter, D. Quantification of cation-π interactions in proteinligand complexes: crystal-structure analysis of factor Xa bound to a quaternary ammonium ion ligand. Angew. Chem. Int. Ed. Engl., 2005, 44, 4400-4404. (Pubitemid 41026381)
36. Gil, A.; Branchadell, V.; Bertran, J.; Oliva, A. CH-π interactions in DNA and proteins. A theoretical study. J. Phys. Chem. B., 2007, 111, 9372-9379. (Pubitemid 47280538)
37. Meyar, E. A.; Castellano, R. K.; Diederich, F. Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed. Engl., 2003, 42, 1210-1250. (Pubitemid 36410287)
38. Ma, J. C.; Dougherty, D. A. The Cation-π interactions. Chem. Rev., 1997, 97, 1303-1324.
39. Reddy, A. S.; Sastry, G. N. Cation [M=H+, Li+, Na+, K+, Ca+, Mg2+, NH4 +, and NMe4 +] interactions with the aromatic motifs of naturally occurring amino acids: A theoretical study. J. Phys. Chem. A, 2005, 109, 8893-8903.
40. Reddy, A. S.; Sastry, G. M.; Sastry, G. N. Cation-Aromatic Database. Proteins: Struc, Func, Bioinfo. 2007, 67, 1179-1184. (Pubitemid 46753962)
41. Mignon, P.; Loverix, S.; Steyaert, J.; Geerlings, P. Influence of the π-π interaction on the hydrogen bonding capacity of stacked DNA/RNA bases. Nucleic Acids Res., 2005, 33, 1779-1789. (Pubitemid 41754207)
42. Vijay, D.; Zipse, H.; Sastry, G. N. On the cooperativity of cation-?c and hydrogen bonding interactions. J. Phys. Chem. B, 2008, 112, 8863-8867.
43. Vijay, D.; Sastry, G. N. The cooperativity of cation-π and π-π interactions. Chem. Phys. Lett., 2010, 485, 235-242.
44. Chourasia, M.; Sastry, G. M.; Sastry, G. N. Aromatic-Aromatic Database, A2ID: An analysis of aromatic π-networks in proteins. Int. J. Biol. Macromol., 2011, 48, 540-552.
45. Mahadevi, A. S.; Rahalkar, A. P.; Gadre, S. R.; Sastry, G. N. J. Chem. Phys., 2010, 133, 164308.
46. Vijay, D.; Sastry, G. N. A computational study on π and π modes of metal ion binding to heteroaromatics (CH)5-mXm and (CH)6-mXm (X = N and P): Contrasting preferences between nitrogen and phosphorous substituted rings. J. Phys. Chem. A, 2006, 110, 10148-10154. (Pubitemid 44376322)
47. Filomia, F.; Rienzo, F. D.; Menziani, M. C. Insights into MAPK p38a DFG flip mechanism by accelerated molecular dynamics. Bioorg. Med. Chem., 2010, 18, 6805-6812.
48. Biot, C.; Wintjens, R.; Rooman, M. Stair motifs at protein-DNA interfaces: nonadditivity of H-bond, stacking, and cation-π interactions. J. Am. Chem. Soc., 2004, 126, 6220-6221. (Pubitemid 38657035)
49. Hu, X.; Balaz, S.; Shelver, W. H. A practical approach to docking of zinc metalloproteinase inhibitors. J. Mol. Graph. Model., 2004, 22, 293-307. (Pubitemid 38183099)
50. Irwin, J. J.; Raushel, F. M.; Shoichet, B. K. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry, 2005, 44, 12316-12328. (Pubitemid 41324325)
51. Khandelwal, A.; Lukacova, V.; Comez, D.; Kroll, D. M.; Raha, S.; Balaz, S. A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands. J. Med. Chem., 2005, 48, 5437-5447. (Pubitemid 41209242)
52. Jain, T.; Jayaram, B. Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes. Proteins: Struct Funct Genet, 2007, 67, 1167-1178. (Pubitemid 46753961)
53. Sharma, B.; Rao, J. S.; Sastry, G. N. Effect of Solvation on Ion Binding to Imidazole and Methylimidazole. J. Phys. Chem. A, 2011, 115, 1971-1984.
54. Mahadevi, A. S.; Sastry, G. N. A theoretical study on interaction of cyclopentadienyl ligand with akali and alkaline earth metals. J. Phys. Chem. B, 2011, 115, 703-710.
55. Rao, J. S.; Dinadayalane, T. C.; Leszczynski, J.; Sastry, G. N. A comprehensive study on the solvation of mono and di valent metal ions: Li+, Na+, K+, Be2+, Mg2+ and Ca2. J. Phys. Chem. A., 2008, 112, 12944-12953.
56. Neela, Y. I.; Mahadevi, A. S.; Sastry, G. N. Hydrogen bonding in water clusters and their ionized counterparts. J. Phys. Chem. B, 2010, 114, 17162-17171.
57. Ludwig, R. Water: From Clusters to the Bulk. Angew. Chem. Int. Ed. Engl., 2001, 113, 1856-1876
58. Searle, M. S.; Williams, D. H. The cost of conformational order: entropy changes in molecular associations. J. Am. Chem. Soc., 1992, 114, 10690-10697.
59. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA, 1981, 78, 4046-4050 (Pubitemid 11010286)
60. Grunwald, E.; Steel, C. Solvent Reorganization and Thermodynamic Enthalpy-Entropy Compensation. J. Am. Chem. Soc., 1995, 117, 5687-5692.
61. Drie, J. H. V.; Lajiness, M. S. Approaches to virtual drug design. Drug Discov. Today, 1998, 3, 274-283.
62. Weber, L.; Wallbaum, S.; Broger, C.; Gubernator, K. Optimization of the biological activity of combinatorial compound libraries by a genetic algorithm. Angew. Chem. Int. Ed. Engl., 1995, 107, 2452-2454.
63. Bissantz, C.; Kuhn, B.; Stahl, M. A Medicinal Chemist's Guide to Molecular Interactions. J. Med. Chem., 2010, 53, 5061-5084.
64. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands. Angew. Chem. Int. Ed. Engl., 2002, 41, 2644-2676.
65. Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C. R. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br. J. Clin. Pharmacol., 2008, 153, S7-S26. (Pubitemid 351340987)
66. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J. Chem. Inf. Model., 2011, 51, 69-82.
67. Jorgensen, W. L. The many roles of computation in drug discovery. Science, 2004, 303, 1813-1818. (Pubitemid 38374866)
68. Jorgensen, W. L. Efficient drug lead discovery and optimization. Acc. Chem. Res., 2009, 42, 724-33.
69. Zhou, T.; Huang, D.; Caflisch, A. Quantum mechanical methods for drug design. Curr. Top. Med. Chem., 2010, 10, 33-45.
70. Raha, K.; Peters, M. B.; Wang, B.; Yu, N.; WollaCott, A. M.; Westerhoff, L. M.; Merz, K. M. The role of quantum mechanics in structure-based drug design. Drug Discov. Today, 2007, 12, 725-731. (Pubitemid 47364833)
71. Onodera, K.; Satou, K.; Hirota H. evaluations of molecular docking programs for virtual screening. J. Chem. Inf. Model., 2007, 47, 1609-1618. (Pubitemid 47210064)
72. McGaughey, G. B.; Sheridan, R. P.; Bayly, C. I.; Culberson, J. C.; Kreatsoulas, C.; Lindsley, S.; Maiorov, V.; Truchon, J. F.; Cornell, W. D. Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model., 2007, 47, 1504-1519. (Pubitemid 47210053)
73. Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y.; Humblet, C. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 2009, 49, 1455-1474.
74. M. Feher. Consensus scoring for protein-ligand interactions. Drug Discovery Today, 2006, 11, 421-428. (Pubitemid 44382521)
75. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem., 2001, 44, 1035-1042. (Pubitemid 32852130)
76. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-1749. (Pubitemid 38380917)
77. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol., 1996, 261, 470-489. (Pubitemid 26335901)
78. Osterberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins: Struct. Funct. Genet., 2002, 46, 34-40. (Pubitemid 34033574)
79. Huang, S. Y.; Zou, X. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking. Proteins: Struct., Funct., Bioinf., 2007, 66, 399-421. (Pubitemid 46053470)
80. Armen, R. S.; Chen, J.; Brooks, C. L. An evaluation of explicit receptor flexibility in molecular docking using molecular dynamics and torsion angle molecular dynamics. J. Chem. Theory Comput., 2009, 13, 2909-2923.
81. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662. (Pubitemid 128590223)
82. Kirchmair, J.; Laggner, C.; Wolber, G.; Langer, T. Comparative analysis of protein-bound ligand conformations with respect to Catalyst's conformational space subsampling algorithms. J. Chem. Inf. Model., 2005, 45, 422-430. (Pubitemid 40635351)
83. Watts, K. S.; Dalal, P.; Murphy, R. B.; Sherman, W.; Friesner, R. A.; Shelley, J. C. ConfGen: A conformational search method for efficient generation of bioactive conformers. J. Chem. Inf. Model., 2010, 50, 534-546.
84. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748. (Pubitemid 27170693)
85. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM - a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem., 1994, 15, 488-506.
86. Wang, R.X.; Wang, S.M. How does consensus scoring work for virtual library screening? An idealized computer experiment. J. Chem. Inf. Comput. Sci., 2001, 41, 1422-1426.
87. Stahl, M.; Bohm, H. J. Development of filter functions for proteinligand docking. J. Mol. Graph. Model., 1998, 16, 121-132. (Pubitemid 32250262)
88. Lin, J.; Sahakian, D. C.; Morais, S. M.; Xu, J. J.; Polzer, R. J.; Winter, S. M. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem., 2003, 3, 1125-1154.
89. Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2,192-204. (Pubitemid 37361664)
90. Darvas, F.; Keseru, G.; Papp, A.; Dorman, G.; Urge, L.; Krajcsi, P. In silico and ex silico ADME approaches for drug discovery. Curr. Top. Med. Chem., 2002, 2, 1287-1304.
91. Ekins, S.; Boulanger, B.; Swaan, P. W.; Hupcey, M. A. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. Mol. Divers. 2002, 5, 255-275.
92. Waterbeemd, H. High throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Devel., 2002, 5, 33-43. (Pubitemid 34453240)
93. Hochlowski, J.; Cheng, X.; Sauer, D.; Djuric, S. Studies of the relative stability of TFA adducts vs non-TFA analogues for combinatorial chemistry library members in DMSO in a repository compound collection. J. Comb. Chem., 2003, 5, 345-350.
94. Balakin, K. V.; Ivanenkov, Y. A.; Skorenko, A. V.; Nikolsky, Y. V.; Savchuk, N. P.; Ivashchenko, A. A. In silico estimation of DMSO solubility of organic compounds for bioscreening. J. Biomol. Scr., 2003, 9, 22-31.
95. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev., 1997, 23, 3-25. (Pubitemid 27046991)
96. Murthy, J. N.; Nagaraju, M.; Sastry, G. M.; Rao, A. R.; Sastry, G. N. Active-site acidic residues and structural analysis of human aromatase: Molecular modeling study based on mammalian CYP 2 C. J. Comp. Mol. Design., 2005, 19, 857-870.
97. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery, 2002, 9, 727-30. (Pubitemid 37361545)
98. Bindu, P. H.; Sastry, G. M.; Sastry, G. N. Characterization of calcium and magnesium binding domains of human5- Lipoxygenase. Biophysic. Biochem. Res. Commun., 2004, 320, 461-467.
99. Bhargavi, R.; Sastry, G. M.; Murty, U. S. N.; Sastry, G. N. Structural and active site analysis of plasmepsins of plasmodium falciiparum; Potential anti-malarial targets. Int. J. Biol. Macromol., 2005, 37, 73-84. (Pubitemid 41539677)
100. Bindu, P. H.; Sastry, G. M.; Murty, U. S. N.; Sastry, G. N. Structural and Conformational Changes Concomitant with the E1- E2 transition in H+K+-ATPase: A comparative protein modeling study. Biophysic. Biochem. Res. Commun., 2004, 319, 312-320. (Pubitemid 38725948)
101. Srivastava, H. K.; Chourasia, M.; Kumar, D.; Sastry, G. N. Comparison of computational methods to model DNA minor groove binders. J. Chem. Inf. Model., 2011, 51, 558-571.
102. Janardhan, S.; Srivani, P.; Sastry, G. N. 2D and 3D quantitative structure-activity relationship studies on a series of bis-pyridinium compounds as choline kinase inhibitors. QSAR & Comb. Sci., 2006, 25, 860-872. (Pubitemid 44621663)
103. Janardhan, S.; Srivani, P.; Sastry, G. N. Choline kinase: An important target for cancer. Curr. Med Chem., 2006, 13, 1169-1186.
104. Mannig, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298, 1912-1934. (Pubitemid 35425239)
105. Noble, M. E. M.; Endicott, J.; Johnson, L. K. Protein kinase inhibitors: Insights into drug design from structure. Science, 2004, 303, 1800-1805. (Pubitemid 38374863)
106. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem., 2010, 53, 1413-1437.
107. Hendriks, B. S.; Seidl, K. M.; Chabot, J. R. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro. BMC Syst. Biol., 2010, 4, 23.
108. Cowan, J. S. W.; Meobitz, H.; Fabbro, D. Structural biology contributions to tyrosine kinase drug discovery. Curr. Opin. Cell Biol., 2009, 21, 280-287.
109. Vulpetti, A.; Bosotti, R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco, 2004, 59, 759-765. (Pubitemid 39335946)
110. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell, 2002, 109, 275-282. (Pubitemid 34606870)
111. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82, 195-206. (Pubitemid 29255915)
112. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, 1998, 281, 533-538. (Pubitemid 28357362)
113. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisà, S.; Cobb, M. H.; Young, P. R.; Meguid, A. S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure, 1998, 6, 1117-1128. (Pubitemid 28434115)
114. Ravindra, G. K.; Achaiah, G.; Sastry, G. N. Novel targets for antiinflammatory and anti-arthritic agents. Curr. Pharm. Design., 2006, 12, 2437-2454.
115. Ravindra, G. K.; Achaiah, G.; Sastry, G. N. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur. J. Med. Chem., 2008, 43, 830-838. (Pubitemid 351446153)
116. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "Gatekeeper door": exploiting the active kinase conformation. J. Med. Chem., 2010, 53, 2681-2694.
117. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science, 2000, 289, 1938-1942.
118. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol., 2002, 9, 268-272. (Pubitemid 34289898)
119. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu, D. D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116, 855-867. (Pubitemid 38410730)
120. Manley, P. W.; Bold, G.; Brüggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta., 2004, 1697, 17-27. (Pubitemid 38326758)
121. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C. A.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A. E.; Jhoti, H. Identification of novel p38π MAP kinase inhibitors using fragment based lead generation. J. Med. Chem., 2005, 48, 414-426. (Pubitemid 40139784)
122. Cumming, J. G.; McKenzie, C. L.; Bowden, S. G.; Campbell, D.; Masters, D. J.; Breed, J.; Jewsbury, P. J. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2004, 14, 5389-5394. (Pubitemid 39359133)
123. Heron, N. M.; Anderson, M.; Blowers, D. P.; Breed, J.; Eden, J. M.; Green, S.; Hill, G. B.; Johnson, T.; Jung, F. H.; McMiken, H. H.; Mortlock, A. A.; Pannifer, A. D.; Pauptit, R. A.; Pink, J.; Roberts, N. J.; Rowsell, S. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 1320-1323. (Pubitemid 43143015)
124. Jung, F. H.; Pasquet, G.; Lambert B.C.; Lohmann, J. J.; Warin, N.; Renaud, F.; Germain, H.; Savi D. C.; Roberts, N.; Johnson, T.; Dousson, C.; Hill, G. B.; Mortlock, A. A.; Heron, N.; Wilkinson, R. W.; Wedge, S. R.; Heaton, S. P.; Odedra, R.; Keen, N. J.; Green, S.; Brown, E.; Thompson, K.; Brightwell, S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J. Med. Chem., 2006, 49, 955-970. (Pubitemid 43221644)
125. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2005, 48, 6066-6083. (Pubitemid 41324615)
126. Lowinger, T.B., Riedl, B., Dumas, J. & Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des., 2002, 8, 2269-2278. (Pubitemid 35189900)
127. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64, 6652-6659. (Pubitemid 39297926)
128. Badrinarayan, P.; Sastry, G. N. Sequence, structure, and active site analyses of p38 MAP kinase: Exploiting DFG-out conformation as a strategy to design new type II leads. J. Chem. Inf. Model., 2010, 51, 115-129.
129. Muller, T.; Engels, P.; Fozard, J. R. Subtypes of the type4 cAMP phosphodiesterase: Structure, regulation and selective inhibition. Trends Pharmacol. Sci., 1996, 17, 294-298. (Pubitemid 26261894)
130. Zhang, K.Y.; Ibrahim, P. N.; Gillette, S.; Bollag, G. Phosphodiesterase 4 as a potential drug target. Exp. Opin. Ther. drugs, 2005, 9, 1283-1304.
131. Giembycz, M. A. 4D or not 4D the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharmacol. Sci., 2002, 23, 548. (Pubitemid 35375796)
132. Sutherland, E. W.; Rall, T. W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 1958, 232, 1077-1091.
133. Jonathan, B.; Sucha, S.; Subha, S. Profiling human phosphodiesterase genes and splice isoforms. Biochem. Biophys. Res. Comm., 2006, 350, 25-32.
134. Beavo, J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 1995, 75, 725-48.
135. Sharron, H. F.; Illarion, V. T.; Jackie, D. C. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol., 2001, 65, 1-52.
136. Barnes, P. J. Theophylline: new perspective for the old drug. Am. J. Respir. Crit. Care Med., 2003, 167, 813-818. (Pubitemid 36801766)
137. Boswell, S. V.; Cazzola, M.; Page, C. P. Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol., 2006, 117, 1237-43. (Pubitemid 43795733)
138. Piaz, D. V.; Giovannoni, M. P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. J. Med. Chem., 2000, 35, 463-480. (Pubitemid 30395096)
139. Burnouf, C.; Pruniaux, M. P. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Design, 2002, 8, 1255-1296. (Pubitemid 34594253)
140. Montana, J. G.; Dyke, H. J. Phosphodiesterase 4 inhibitors. Ann. Rep. Med. Chem. 2001, 36, 41-56.
141. Souness, J. E.; Rao, S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal., 1997, 9, 227-236. (Pubitemid 27271642)
142. Barnette, M. S.; Bartus, J.O.; Burman, M.; Christensen, S. B.; Cieslinski, L. B.; Esser, K. M.; Prabhakar, U. S.; Rush, J. A.; Torphy, T. J. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding. Biochem. Pharmacol., 1996, 51, 949-956. (Pubitemid 26111151)
143. Duplantier, A. J.; Biggers, M. S.; Chambers, R. J.; Cheng, J. B.; Cooper, K.; Damon, D. B.; Eggler, J. F.; Kraus, K. G.; Marfat, A.; Masamune, H.; Pillar, J. S.; Shirley, J. T.; Umland, J. P.; Watson, J. W. Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [3H] rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem., 1996, 39, 120-125. (Pubitemid 26027021)
144. Zhang, H. T.; Zhao, Y.; Huang, Y.; Deng, C.; Hopper, A. T.; Vivo, M. D.; Rose, G. M.; O'Donnell, J. M. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology, 2006, 186, 209-217. (Pubitemid 43727338)
145. Spina, D. The potential of PDE4 inhibitors in respiratory disease. Curr. Drug Targ. Inflamm. Allergy, 2004, 3, 231-246.
146. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE4) inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol. Sci., 1997, 18, 164-171.
147. Chung, K. F. Phosphodiesterase inhibitors in airways disease. Eur. J. Pharm., 2006, 533, 110-117.
148. Deng, Y.; Qiang-min, X.; Hui-fang, T.; Jian-gang, S.; Jun-fang, D.; Ji-qiang, C.; Zhejiang, Y. S. Effects of ciclamilast, a new PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur. J. Pharm., 2006, 547, 125-135. (Pubitemid 44376758)
149. Manning, C. D.; Burman, M.; Christensen, S. B.; Cieslinski, L. B.; Essayan, D. M.; Grous, M.; Torphy, T. J.; Barnette, M. S. Suppression of human inflammatory cell function by subtypeselective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol., 1999, 128, 1393-1398.
150. Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs, M.; Wigler, M.; Ferguson, K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster is potential targets for antidepressant drugs. Mol. Cell. Biol., 1993, 13, 6558-6571. (Pubitemid 23292650)
151. Houslay, M. D. PDE4-cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol., 2001, 69, 249-315.
152. Bolger, G. B.; Erdogan, S.; Jones, R. E.; Loughney, K.; Scotland, G.; Hoffmann, R.; Wilkinson, I.; Farrell, C.; Houslay, M. D. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J., 1997, 328, 539-548. (Pubitemid 27515598)
153. Polymeropoulos, E. E.; Hofgen, N. A peptidic binding site model for PDE4 Inhibitors. QSAR, 1999, 18, 543-547. (Pubitemid 30018844)
154. Salter, E. A.; Wierzbicki, A. The mechanism of cyclic nucleotide hydrolysis in the phosphodiesterase catalytic site. J. Phy. Chem. B., 2007, 111, 4547-4552. (Pubitemid 46787651)
155. Salter, E. A.; O'Brien, K. A.; Edmunds, R. W.; Wierzbicki, A. ONIOM investigation of nucleotide selectivity in phosphodiesterases 3 and 4. Int. J. of Quant. Chem., 2008, 108, 1189-1199. (Pubitemid 351378803)
156. Xiong, Y.; Lu, H-T.; Li, Y.; Yang, G. F.; Zhan, C. G. Characterization of a catalytic ligand bridging metal ions in PDE4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations. Biophys. J., 2006, 91, 1858-1867. (Pubitemid 44352449)
157. Kang, N. S.; Chae, C. H.; Yoo, S. E. Study on the hydrolysis mechanism of phosphodiesterase 4 using molecular dynamics simulations. Mol. Simul., 2006, 32, 369-374. (Pubitemid 44371348)
158. Krier, M.; de Araujo-Junior, J. X.; Schmitt, M.; Duranton, J.; Basaran,
159. Srivani, P.; Usharani, D.; Jemmis, E. D.; Sastry, G. N. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr. Pharma. Design, 2008, 14, 3854-3872.
160. Usharani, D.; Srivani, P.; Sastry, G. N.; Jemmis, E. D. A pH dependence of 310-helix versus turn in m-loop region of PDE4: Observations on PDB entries and an electronic structure study. J. Chem. Theory Comput., 2008, 4, 974-984.
161. Dinadayalane, T. C.; Sastry, G. N.; Leszczynski, J. Comprehensive theoretical study towards the accurate proton affinity values of naturally occurring amino acids. Int. J. Quant. Chem., 2006, 106, 2920-2933. (Pubitemid 44726730)
162. Badrinarayan, P.; Srivani, P.; Sastry, G. N. Design of 1- arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors. J Mol. Model., 2010, DOI: 10.1007/s00894-010-0752-2.
163. Srivani, P.; Kiran, K.; Sastry, G. N. Understanding the structural requirements of triarylethane analogues towards PDE-IV inhibitors: A molecular modeling study. Ind. J. Chem. A, 2006, 45A, 68-76. (Pubitemid 43479778)
164. Kulkarni, G. K.; Srivani, P.; Achiah, G.; Sastry, G. N. Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: A molecular modeling study. J. Comp. -Aided Mol. Des., 2007, 21, 155-166. (Pubitemid 46510841)
165. Srivani, P.; Srinivas, E.; Raghu, R.; Sastry, G. N. Molecular modeling studies of pyridopurinone derivatives - Potential phosphodiesterase5 inhibitors. J. Mol. Graphics Modell., 2007, 26, 378-390. (Pubitemid 46992725)
166. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745. (Pubitemid 30650186)
167. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution threedimensional structure of rhodopsin, a model of G-proteincoupled receptors (GPCRs). Biochemistry, 2001, 40, 7761-7772. (Pubitemid 32622966)
168. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein coupled receptor. Science, 2007, 318, 1258-1265. (Pubitemid 350172884)
169. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields highresolution structural insights into π2-adrenergic receptor function. Science, 2007, 318, 1266-1273. (Pubitemid 350172885)
170. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D.M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic Gprotein- coupled receptor. Nature, 2007, 450, 383-387. (Pubitemid 350126755)
171. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V.P.; Chien, E. Y.; Velasquez, J.; Kuhn, P.; Stevens, R. C. A specific cholesterol binding site is established by the 2.8 a structure of the human π2-adrenergic receptor. Structure, 2008, 16, 897-905. (Pubitemid 351778384)
172. Warne, T.; Vega, M. J. S.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a π1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
173. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature, 2008, 454, 183-187. (Pubitemid 351969893)
174. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of opsin in its G-protein-interacting conformation. Nature, 2008, 455, 497-502.
175. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins, 2003, 50, 5-25. (Pubitemid 36090604)
176. Evers, A.; Hessler, G.; Matter, H.; Klabunde, T. Virtual screening of biogenic amine-binding G-protein coupled receptors: Comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem., 2005, 48, 5448-5465. (Pubitemid 41209243)
177. Schlyer, S.; Horuk, R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today, 2006, 11, 481-493.
178. Ghosh, S.; Nie, A.; An, J.; Z. Huang. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol., 2006, 10,194-202. (Pubitemid 43815778)
179. Klebe, G. Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov. Today, 2006, 11, 580-594.
180. Taylor, C. M.; Barda, Y.; Kisselev, O. G.; Marshall, G. R. Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J. Med. Chem., 2008, 51, 5297-5303.
181. Kubinyi, H. Success Stories of Computer-Aided Design, In: Computer Applications in Pharmaceutical Research and Development, Ekins, S. Ed.; [Wiley Series in Drug Discovery and Development (Wang, B. Ed.)], Wiley-Interscience, 2006, 377-424.
182. Eckert, H.; Bajorath, J. Determination and mapping of activityspecific descriptor value ranges (MAD) for the identification of active compounds. J. Med. Chem., 2006, 49, 2284-2293.
183. Godden, J. W.; Furr, J. R.; Xue, L.; Stahura, F. L.; Bajorath, J. Molecular similarity analysis and virtual screening in binarytransformed chemical descriptor spaces with variable dimensionality. J. Chem. Inf. Comput. Sci., 2004, 44, 21-29.
184. Godden, J. W.; Furr, J. R.; Stahura, F. L.; Bajorath, J. POT-DMC: a virtual screening method for the identification of potent hits. J. Med. Chem., 2004, 47, 5608-5611. (Pubitemid 39447256)
185. Eckert, H.; Vogt, I.; Bajorath, J. Mapping algorithms for molecular similarity analysis and ligand-based virtual screening: design of DynaMAD and comparison with MAD and DMC. J. Chem. Inf. Model., 2006, 46, 1623-1634. (Pubitemid 44185689)
186. Godden, J.W.; Bajorath, J. A distance function for retrieval of active molecules from complex chemical space representations. J. Chem. Inf. Model.; 2006, 46, 1094-1097. (Pubitemid 43999154)
187. Vogt, M.; Godden, J. W.; Bajorath, J. Bayesian interpretation of a distance function for navigating high-dimensional descriptor spaces. J. Chem. Inf. Model., 2007, 38, 1522-2667.
188. Willett, P. Searching techniques for databases of two- and threedimensional chemical structures. J. Med. Chem., 2005, 48, 4183-4199. (Pubitemid 40884919)
189. Pearlman, R.S.; Smith, K.M. Novel software tools for chemical diversity. Perspect. Drug Discovery Des., 1998, 9, 339-353. (Pubitemid 128491931)
190. Harper, G.; Bradshaw, J.; Gittins, J. C.; Green, D. V.; Leach, A. R. Prediction of biological activity for high throughput screening using binary kernel discrimination. J. Chem. Inf. Comput. Sci., 2001, 41, 1295-1300.
191. Warmuth, M. K.; Liao, J.; Rätsch, G.; Mathieson, M.; Putta, S.; Lemmen, C. Active learning with support vector machines in the drug discovery process. J. Chem. Inf. Comput. Sci., 2003, 43, 667-673.
192. Jorissen, R.N.; Gilson, M.K. Virtual screening of molecular databases using a support vector machine. J. Chem. Inf. Model., 2005, 45, 549-561. (Pubitemid 40795161)
193. James, C.A.; Weininger, D. Daylight theory manual; Daylight Chemical Information Systems, Inc. of Aliso Viejo, CA, 2006.
194. Bender, A.; Mussa, H. Y.; Glen, R. C. Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J. Chem. Inf. Comput. Sci., 2004, 44, 1708-1718.
195. Eckert, H.; Bajorath, J. Design and evaluation of a novel classdirected 2D fingerprint to search for structurally diverse active compounds. J. Chem. Inf. Model., 2006, 46, 2515-2526. (Pubitemid 46008123)
196. Haigh, J. A.; Pickup, B. T.; Grant, J. A.; Nicholls, A. Small molecule shape-fingerprints. J. Chem. Inf. Model., 2005, 45, 673-684. (Pubitemid 40795171)
197. Saeh, J.C.; Lyne, P. D.; Takasaki, B. K.; Cosgrove, D. A. Lead hopping using SVM and 3D pharmacophore fingerprints. J. Chem. Inf. Model., 2005, 45, 1122-1133. (Pubitemid 41161731)
198. Bender, A.; Jenkins, J. L.; Glick, M.; Deng, Z.; Nettles, J. H.; Davies, J. W. Bayes affinity fingerprints'' improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? J. Chem. Inf. Model., 2006, 46, 2445-2456. (Pubitemid 46008117)
199. Grant, J.A. Lingos, finite state machines, and fast similarity searching. J. Chem. Inf. Model., 2006, 46, 1912-1918. (Pubitemid 44625962)
200. Batista, J.; Godden, J. W.; Bajorath J. Assessment of molecular similarity from the analysis of randomly generated structural fragment populations. J. Chem. Inf. Model., 2006, 46, 1937-1944. (Pubitemid 44625965)
201. Batista, J.; Bajorath, J. Chemical database mining through entropybased molecular similarity assessment of randomly generated structural fragment populations. J. Chem. Inf. Model., 2007, 47, 59-68. (Pubitemid 46225560)
202. Gillet, V. J.; Willett, P.; Bradshaw, J. Similarity searching using reduced graphs. J. Chem. Inf. Comput. Sci., 2003, 43, 338-345.
203. Rush III, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shapebased 3D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem., 2005, 48, 1489-1495. (Pubitemid 40364556)
204. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional proteinligand binding interactions. J. Med. Chem., 2004, 47, 337-344. (Pubitemid 38057878)
205. Prez-Nueno, V. I.; Rabal, O.; Borrell, J. I.; Teixid, J.APIF: A new Interaction fingerprint based on atom pairs and its application to virtual screening. J. Chem. Inf. Model., 2009, 49, 1245-1260.
206. Sato, T.; Honma, T.; Yokoyama, S. Combining machine learning and pharmacophore-based interaction fingerprint for in silico screening. J. Chem. Inf. Model., 2010, 50, 170-185.
207. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins, 2004, 57, 225-242. (Pubitemid 39223729)